REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Clear Cell Renal Cell Carcinoma (ccRCC)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 265 (planned)
- Started
- Jul 20, 2026
- Main results expected
- Oct 27, 2030
- Fully finished
- Oct 27, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Occurrence of Dose Limiting Toxicities (DLTs)
Measured over: Up to 5 years
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Measured over: Up to 5 years
Occurrence of Serious Adverse Events (SAEs)
Measured over: Up to 5 years
Occurrence of Adverse Events of Special Interest (AESIs)
Measured over: Up to 5 years
Composite Response (CompR) based on ≥50% decline of Prostate Specific Antigen (PSA) and/or confirmed radiographic assessment of complete response (CR) or partial response (PR)
Measured over: Up to 5 years
Objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measured over: Up to 5 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07594106 · record last updated 2026-09-28 · checked 2026-11-09 15:47 UTC